Beam Therapeutics

Beam Therapeutics Inc.
Company type	Public
Traded as	Nasdaq: BEAM; Russell 2000 component;
ISIN	US07373V1052
Industry	Biotechnology
Founded	2017; 7 years ago
Founders	David R. Liu; J. Keith Joung; Feng Zhang; Nicole Gaudelli; Alexis Komor;
Headquarters	Cambridge, Massachusetts, U.S.
Key people	John Evans (CEO); Giuseppe Ciaramella (CSO);
Number of employees	341 (December 31, 2021)
Website	beamtx.com

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods^[vague].^[2]^[3]

History[edit]

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.^[4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.^[5]

In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.^[6]^[7]

References[edit]

^ "Beam Therapeutics Inc. FORM 10-K". U.S. Securities and Exchange Commission. Retrieved 14 December 2022.
^ "Why Beam Therapeutics Climbed 64.5% in June". NASDAQ. Archived from the original on 2021-08-07.
^ Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-08-07.
^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN 978-1-9821-1585-2.
^ Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma". Business Insider. Retrieved 2021-08-07.
^ "Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases". Pfizer.
^ Alpert, Bill. "Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases". www.barrons.com. Retrieved 2022-02-04.

External links[edit]

Official website
Business data for Beam Therapeutics Inc.:

[1] "Beam Therapeutics Inc. FORM 10-K". U.S. Securities and Exchange Commission. Retrieved 14 December 2022.

[2] "Why Beam Therapeutics Climbed 64.5% in June". NASDAQ. Archived from the original on 2021-08-07.

[3] Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-08-07.

[4] Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN 978-1-9821-1585-2.

[5] Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma". Business Insider. Retrieved 2021-08-07.

[6] "Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases". Pfizer.

[7] Alpert, Bill. "Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases". www.barrons.com. Retrieved 2022-02-04.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

History[edit]

See also[edit]

References[edit]

External links[edit]